Page 333 - Binder2

The same facility footprint can be expanded modularly.
There’s no need to wait three years for a new bioreactor to
be built or revalidated. There’s no cold-chain bottleneck.
There’s no sterile injection bottleneck. There’s just
biomass—and it scales beautifully.

This isn’t just a cost savings. It’s a structural inversion.

In the old model, scale demands capital.
In the new model, scale demands sunlight and square
footage.

The cost curves don’t just bend—they flatten. They open
up new geographies, new patient populations, and entirely
new possibilities for access.

And in doing so, they don’t just disrupt manufacturing.

They decentralize power.

One of the most overlooked advantages of edible biologics
is that they don’t require a centralized industrial
complex to produce. Traditional biopharmaceutical
manufacturing demands multimillion-dollar facilities,
highly trained personnel, specialized cleanrooms, and
complex cold-chain logistics. As a result, biologic
production has become geographically concentrated—often
limited to a few nations with the capital, regulatory
infrastructure, and technological capability to support it.

But edible biologics flip that model on its head.
They offer a future where drugs can be made near the
point of care, not thousands of miles away.

331